Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reparestim
- Development stage
- Unknown
- Lead developer
- Skin Tech Pharma Group
- Modality
- Peptides, Small Molecules
- Administration
- Topical, Transdermal
01
Overview
Reparestim is a line of professional-grade cosmeceutical products developed by Skin Tech Pharma Group, specifically designed for skin biorevitalization, repair, and rejuvenation. The product line consists of transdermal cocktails that combine hyaluronic acid with a synergistic blend of vitamins, antioxidants, and peptides. These formulations are intended to address aged, oxidized, or damaged skin by providing deep hydration, reducing the appearance of fine lines, and promoting tissue regeneration. Reparestim is typically used in professional aesthetic settings and is often administered in conjunction with technologies such as microneedling, radiofrequency, electrophoresis, or laser treatments to enhance transdermal delivery and efficacy. While manufactured under medical device and cosmetic GMP standards (ISO 13485 and ISO 22716), Reparestim is positioned as an aesthetic treatment rather than a traditional pharmaceutical drug.
- Brand names
- ReparestimReparestim HA TDReparestim Eyes TD
Beyond the preview
Go deeper on Reparestim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reparestim.